Phase II trial of weekly nab-paclitaxel with GM-CSF as an immune modulator in recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer: Clinical and immune responses.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback